An interview with Bjorg K. Hunter, Device Engineering Manager from GSK ahead of Pre-Filled Syringes Europe 2018
A debate on the impact of PFS regulation at Pre-Filled Syringes 2018…
SMi Group will welcome the expertise of Bjorg K. Hunter, Device Engineering Manager from GSK, when she participates on a panel debate at Pre-Filled Syringes Europe 2018 alongside West Pharmaceutical Services, Novartis Pharma AG and Merck.
The conference and exhibition will return to Central London next January for its 10th annual instalment and has already attracted a global audience of attendees from Austria, Belgium, Denmark, France, Germany, Italy, Japan, Netherlands, Switzerland, United Kingdom and USA.
The debate on regulation within the PFS industry will cover topics surrounding the impact of regulation on established products; implications of regulation on the management of difficult formulations; the future of market surveillance; and adapting to current regulations.
“I am specifically interested in the development of combination devices and the regulatory requirement leading up to file,” said Bjorg Hunter.
When asked about current challenges within the PFS industry, she said
“Materials, how can we adopt different materials and break out of the “glass box”. For combination products as a whole I think there is a lot of challenge at the moment in the changing regulatory environment. There is a high focus on devices from regulator, which is great, but also challenging.”
Bjorg Hunter has held various roles within the Device Engineering Group at GSK and has progressed into leading a device management team where she has the overall accountability of device development for parenteral projects.
The full interview is available online in the event download centre.
SMi’s 10th annual 2018 Pre-Filled Syringes Europe conference and exhibition will take place on 17th & 18th Jan at the Copthorne Tara Hotel, Kensington, London UK.
Further information including a detailed agenda and full speaker line-up is available at http://www.pre-filled-syringes.com/drugtargetpr